ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,217.31
0.06%
Dow Jones
39,485.40
0.25%
US Dollar vs MXN
16.77375
-0.12%
Brent Oil
82.825
-1.34%
Bitcoin
60,902.07
-3.40%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) Noticias

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:OKYO
FechaHoraFuenteTítuloSímboloCompañía
08/05/202406:00UK RegulatoryOKYO Pharma Announces Participation in May 2024 Investor ConferencesLSE:OKYOOkyo Pharma Limited
30/04/202406:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
08/04/202418:00UK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
02/04/202406:00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
22/03/202406:00UK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
21/03/202406:00UK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
20/03/202406:00UK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
09/02/202406:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
31/01/202406:00UK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
22/05/202302:15UK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
22/05/202302:00UK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
19/05/202305:22Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
19/05/202302:00RNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
15/05/202301:00UK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
11/05/202308:27Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
11/05/202306:00RNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
11/05/202301:00UK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
03/05/202307:00UK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
03/05/202301:00RNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
02/05/202314:16Alliance NewsAlliance NewsTRADING UPDATES: Knights Group buys St James Law and Baines WilsonLSE:OKYOOkyo Pharma Limited
02/05/202301:00UK RegulatoryOKYO Pharma Limited First-Patient First-Visit for Phase 2 TrialLSE:OKYOOkyo Pharma Limited
25/04/202310:19Alliance NewsAlliance NewsTRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facilityLSE:OKYOOkyo Pharma Limited
25/04/202301:00UK RegulatoryOKYO Pharma Limited Activation of First Clinical Trial Site in the U.SLSE:OKYOOkyo Pharma Limited
05/04/202301:00UK RegulatoryOKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATIONLSE:OKYOOkyo Pharma Limited
04/04/202303:08Alliance NewsAlliance NewsOkyo Pharma applies to delist from London Stock Exchange due to costsLSE:OKYOOkyo Pharma Limited
04/04/202301:00UK RegulatoryOKYO Pharma Limited Notice Of Intention To Delist From The LSELSE:OKYOOkyo Pharma Limited
30/03/202301:00UK RegulatoryOKYO Pharma Limited Director Acquires SharesLSE:OKYOOkyo Pharma Limited
29/03/202301:00UK RegulatoryOKYO Pharma Limited Director acquires sharesLSE:OKYOOkyo Pharma Limited
24/03/202302:00UK RegulatoryOKYO Pharma Limited Director/PDMR ShareholdingLSE:OKYOOkyo Pharma Limited
16/03/202302:01RNS Non-RegulatoryOKYO Pharma Limited Listing of Trial on the ClinicalTrials.gov WebsiteLSE:OKYOOkyo Pharma Limited
 Showing the most relevant articles for your search:LSE:OKYO

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
FX
EURMXN
Euro vs MXN
USI
USTECH100
US Tech 100
USOTC
ADDYY
Adidas (QX)
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
NYSE
JPM
JP Morgan Chase
NYSE
XOM
Exxon Mobil
SPI
SP500
S&P 500
AMEX
XLF
Financial Select Sector
NYSE
BAC
Bank of America
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados